Accumulating evidence indicates the serine protease inhibitor (SERPIN) superfamily plays essential roles in the onset and progression of multiple neurodegenerative disease.[18, 19, 20] A study of 708 prospectively collected autopsied brains revealed lower serine protease inhibitor F1 (SERPINF1) levels in subjects with AD and individuals who were pre‐symptomatic,[21] suggesting that SERPINF1 deficiency may be an essential feature associated with the onset and progression of AD. Here, SERPINF1 is linked to neurodegenerative disease.